Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Descemet stripping only

  • Home
  • Descemet stripping only
Ripasudil After DSO in Fuchs Endothelial Corneal Dystrophy: A Randomized Trial Signals a New Path to Corneal Recovery
Posted innews Ophthalmology

Ripasudil After DSO in Fuchs Endothelial Corneal Dystrophy: A Randomized Trial Signals a New Path to Corneal Recovery

Posted by MedXY By MedXY 06/19/2026
A phase 2 randomized trial found that topical ripasudil after DSO improved endothelial cell density, sped edema clearance, and reduced rescue therapy in FECD, especially with QID dosing.
Read More
  • Parkinson’s Disease Genetics Across Diverse Ancestries: An Observational Genetic Study of Causal and Risk Variants with Translational Implications
  • Prognostic Stratification and Outcomes in Brain Metastases from Nonanaplastic Follicular Cell-Derived Thyroid Carcinoma: Insights from a Multicenter Retrospective Study
  • Metabolic Implications of Hepatic, Pancreatic, and Abdominal Fat Depots in Asian Indians Across Normoglycaemia, Prediabetes, and Type 2 Diabetes
  • Once-Weekly Somapacitan: A New Frontier in Growth Hormone Therapy for Girls with Turner Syndrome
  • Melatonin’s Impact on Glucose Metabolism: Risk Amplified by MTNR1B Diabetes Variant
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in